NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

Mairéad G. McNamara,Jayne Swain,Zoe Craig,Jonathan Wadsley,Nick Reed,Olusola Olusesan Faluyi,Angela Lamarca,Richard A. Hubner,Wasat Mansoor,Debashis Sarker,Helen Howard,David A. Cairns,Tim Meyer,Juan W. Valle

NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).

2019

Mairéad G. McNamara
Jayne Swain
Zoe Craig
Jonathan Wadsley
Nick Reed
Olusola Olusesan Faluyi
Angela Lamarca
Richard A. Hubner
Wasat Mansoor
Debashis Sarker
Helen Howard
David A. Cairns
Tim Meyer
Juan W. Valle

TPS4158Background: The prognosis for pts with PD-EP-NEC is poor. First-line treatment for advanced disease is etoposide/platinum-based chemotherapy, analogous to that of high grade lung NEC, with n...

Keywords:

Fluorouracil
Carcinoma
Oncology
Folinic acid
Pathology
Second-line therapy
Liposomal Irinotecan
Internal medicine
Docetaxel
Medicine
Lung
Clinical trial
Etoposide
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations